Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals has reported positive results from its Phase 1b/2 TUPELO trial for REC-4881, a treatment targeting Familial Adenomatous Polyposis (FAP). This success has strengthened its ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

So far, running LLMs has required a large amount of computing resources, mainly GPUs. Running locally, a simple prompt with a typical LLM takes on an average Mac ...

RAPTOR introduces a novel approach to retrieval-augmented language models by constructing a recursive tree structure from documents. This allows for more efficient and context-aware information ...

Abstract: Complicated deformation problems are frequently encountered in medical image registration tasks. Although various advanced registration models have been proposed, accurate and efficient ...

Abstract: Online collision-free trajectory generation within a shared workspace is fundamental for most multirobot applications. However, many widely-used methods based on model predictive control ...